These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11319589)

  • 1. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response.
    Lamb LS; Musk P; Ye Z; van Rhee F; Geier SS; Tong JJ; King KM; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Mar; 27(6):601-6. PubMed ID: 11319589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
    Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
    Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
    Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H
    Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
    Jurickova I; Waller EK; Yeager AM; Boyer MW
    Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
    Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of alloreactivity with gamma delta T-cells: relevance to increased gamma delta T-cells following bone marrow transplantation.
    Nagai M; Azuma E; Qi J; Kumamoto T; Hiratake S; Hirayama M; Umemoto M; Komada Y; Sakurai M
    Biomed Pharmacother; 1998; 52(3):137-42. PubMed ID: 9755807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.
    Montagna D; Locatelli F; Calcaterra V; Comoli P; Moretta A; Giorgiani G; Zecca M; Bonetti F; Giraldi E; Rondini G; Maccario R
    Bone Marrow Transplant; 1998 Oct; 22(8):743-50. PubMed ID: 9827970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia.
    Nijmeijer BA; van Schie ML; Verzaal P; Willemze R; Falkenburg JH
    Exp Hematol; 2005 Oct; 33(10):1172-81. PubMed ID: 16219539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.